AI assistant
Cartesian Therapeutics, Inc. — Director's Dealing 2017
Jul 5, 2017
33483_dirs_2017-07-05_24c45808-6b9c-4007-b3e0-9922e0699f10.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2017-06-30
Reporting Person: Siewers David (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-06-30 | Common Stock | M | 7420 | $0.63 | Acquired | 7420 | Direct |
| 2017-06-30 | Common Stock | S | 7420 | $20.0007 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-06-30 | Employee Stock Option (right to buy) | $0.63 | M | 7420 | Disposed | 2020-09-06 | Common Stock (7420) | Direct |
Footnotes
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 21, 2016.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: All shares underlying this option are fully vested.